Skip to main content
SpringerLink
Log in

Prevention and Treatment of Infectious Complications in Haploidentical SCT

  • Chapter
  • First Online:
Haploidentical Stem Cell Transplantation

Part of the book series: Stem Cell Biology and Regenerative Medicine ((STEMCELL))

  • 402 Accesses

Abstract

Infectious complications remain a significant cause of morbidity and mortality in patients undergoing hematopoietic stem cell transplantation (HSCT). The increased risk for infections which may be caused by bacteria, viruses, fungi or parasites is due to the complex immune suppression as a consequence of (myeloablative) chemotherapy, immunosuppression induced by conditioning, and immunosuppressive therapy for the prophylaxis or the management of acute and chronic graft-versus-host disease (GvHD). The immunosuppression may affect different arms of the immune system including skin, mucosa, phagocytes, various lymphocyte subsets, cytokines, and interferons. Notably, HSCT with haploidentical donor (haplo-HSCT) is associated with a higher risk of severe GvHD and graft failure which require a more profound immunosuppression than conventional HSCT. Hence, infectious complications are particular frequent and potentially severe in haplo-HSCT.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Lehrnbecher T, Foster C, Vazquez N, et al. Therapy-induced alterations in host defense in children receiving therapy for cancer. J Pediatr Hematol Oncol. 1997;19:399–417.

    Article  CAS  PubMed  Google Scholar 

  2. Lehrnbecher T, Koehl U, Wittekindt B, et al. Changes in host defence induced by malignancies and antineoplastic treatment: implication for immunotherapeutic strategies. Lancet Oncol. 2008;9:269–78.

    Article  CAS  PubMed  Google Scholar 

  3. Chang YJ, Zhao XY, Huo MR, et al. Immune reconstitution following unmanipulated HLA-mismatched/haploidentical transplantation compared with HLA-identical sibling transplantation. J Clin Immunol. 2012;32:268–80.

    Article  CAS  PubMed  Google Scholar 

  4. Sauter C, Abboud M, Jia X, et al. Serious infection risk and immune recovery after double-unit cord blood transplantation without antithymocyte globulin. Biol Blood Marrow Transplant. 2011;17:1460–71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Ciurea SO, Mulanovich V, Saliba RM, et al. Improved early outcomes using a T cell replete graft compared with T cell depleted haploidentical hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2012;18:1835–44.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Collin BA, Leather HL, Wingard JR, et al. Evolution, incidence, and susceptibility of bacterial bloodstream isolates from 519 bone marrow transplant patients. Clin Infect Dis. 2001;33:947–53.

    Article  CAS  PubMed  Google Scholar 

  7. Srinivasan A, Wang C, Srivastava DK, et al. Timeline, epidemiology, and risk factors for bacterial, fungal, and viral infections in children and adolescents after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2013;19:94–101.

    Article  PubMed  Google Scholar 

  8. Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant. 2009;15:1143–238.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Balletto E, Mikulska M. Bacterial infections in hematopoietic stem cell transplant recipients. Mediterr J Hematol Infect Dis. 2015;7:e2015045.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Aversa F, Prezioso L, Manfra I, et al. Immunity to infections after haploidentical hematopoietic stem cell transplantation. Mediterr J Hematol Infect Dis. 2016;8:e2016057.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Crocchiolo R, Bramanti S, Vai A, et al. Infections after T-replete haploidentical transplantation and high-dose cyclophosphamide as graft-versus-host disease prophylaxis. Transpl Infect Dis. 2015;17:242–9.

    Article  CAS  PubMed  Google Scholar 

  12. Meunier F, Lukan C. The First European Conference on Infections in Leukaemia - ECIL1: a current perspective. Eur J Cancer. 2008;44:2112–7.

    Article  PubMed  Google Scholar 

  13. Tramsen L, Salzmann-Manrique E, Bochennek K, et al. Lack of effectiveness of neutropenic diet and social restrictions as anti-infective measures in children with acute myeloid leukemia: an analysis of the AML-BFM 2004 trial. J Clin Oncol. 2016;34:2776–83.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Gardner A, Mattiuzzi G, Faderl S, et al. Randomized comparison of cooked and noncooked diets in patients undergoing remission induction therapy for acute myeloid leukemia. J Clin Oncol. 2008;26:5684–8.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Lehrnbecher T, Phillips R, Alexander S, et al. Guideline for the management of fever and neutropenia in children with cancer and/or undergoing hematopoietic stem-cell transplantation. J Clin Oncol. 2012;30:4427–38.

    Article  PubMed  Google Scholar 

  16. Averbuch D, Orasch C, Cordonnier C, et al. European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia. Haematologica. 2013;98:1826–35.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Mikulska M, Viscoli C, Orasch C, et al. Aetiology and resistance in bacteraemias among adult and paediatric haematology and cancer patients. J Infect. 2014;68:321–31.

    Article  PubMed  Google Scholar 

  18. Averbuch D, Cordonnier C, Livermore DM, et al. Targeted therapy against multi-resistant bacteria in leukemic and hematopoietic stem cell transplant recipients: guidelines of the 4th European Conference on Infections in Leukemia (ECIL-4, 2011). Haematologica. 2013;98:1836–47.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Sangil A, Xercavins M, Rodriguez-Carballeira M, et al. Impact of vaccination on invasive pneumococcal disease in adults with focus on the immunosuppressed. J Infect. 2015;71:422–7.

    Article  PubMed  Google Scholar 

  20. Ardanuy C, de la Campa AG, Garcia E, et al. Spread of Streptococcus pneumoniae serotype 8-ST63 multidrug-resistant recombinant clone, Spain. Emerg Infect Dis. 2014;20:1848–56.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Menzies D, Pai M, Comstock G. Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research. Ann Intern Med. 2007;146:340–54.

    Article  PubMed  Google Scholar 

  22. Boeckh M, Nichols WG, Papanicolaou G, et al. Cytomegalovirus in hematopoietic stem cell transplant recipients: current status, known challenges, and future strategies. Biol Blood Marrow Transplant. 2003;9:543–58.

    Article  PubMed  Google Scholar 

  23. Nichols WG, Corey L, Gooley T, et al. High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV)-seronegative recipients of stem cell transplants from seropositive donors: evidence for indirect effects of primary CMV infection. J Infect Dis. 2002;185:273–82.

    Article  PubMed  Google Scholar 

  24. Boeckh M, Fries B, Nichols WG. Recent advances in the prevention of CMV infection and disease after hematopoietic stem cell transplantation. Pediatr Transplant. 2004;8(Suppl 5):19–27.

    Article  PubMed  Google Scholar 

  25. Ljungman P, Hakki M, Boeckh M. Cytomegalovirus in hematopoietic stem cell transplant recipients. Hematol Oncol Clin North Am. 2011;25:151–69.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Boeckh M, Boivin G. Quantitation of cytomegalovirus: methodologic aspects and clinical applications. Clin Microbiol Rev. 1998;11:533–54.

    CAS  PubMed  PubMed Central  Google Scholar 

  27. Boeckh M, Gooley TA, Myerson D, et al. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. Blood. 1996;88:4063–71.

    CAS  PubMed  Google Scholar 

  28. Reusser P, Einsele H, Lee J, et al. Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation. Blood. 2002;99:1159–64.

    Article  CAS  PubMed  Google Scholar 

  29. Chakrabarti S, Collingham KE, Osman H, et al. Cidofovir as primary pre-emptive therapy for post-transplant cytomegalovirus infections. Bone Marrow Transplant. 2001;28:879–81.

    Article  CAS  PubMed  Google Scholar 

  30. Ljungman P, Deliliers GL, Platzbecker U, et al. Cidofovir for cytomegalovirus infection and disease in allogeneic stem cell transplant recipients. The Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Blood. 2001;97:388–92.

    Article  CAS  PubMed  Google Scholar 

  31. Prentice HG, Gluckman E, Powles RL, et al. Long-term survival in allogeneic bone marrow transplant recipients following acyclovir prophylaxis for CMV infection. The European Acyclovir for CMV Prophylaxis Study Group. Bone Marrow Transplant. 1997;19:129–33.

    Article  CAS  PubMed  Google Scholar 

  32. Neuenhahn M, Albrecht J, Odendahl M, et al. Transfer of minimally manipulated CMV-specific T cells from stem cell or third-party donors to treat CMV infection after alloHSCT. Leukemia. 2017. [Epub ahead of print]

    Google Scholar 

  33. Ruutu T, Ljungman P, Brinch L, et al. No prevention of cytomegalovirus infection by anti-cytomegalovirus hyperimmune globulin in seronegative bone marrow transplant recipients. The Nordic BMT Group. Bone Marrow Transplant. 1997;19:233–6.

    Article  CAS  PubMed  Google Scholar 

  34. Thorley-Lawson DA, Gross A. Persistence of the Epstein-Barr virus and the origins of associated lymphomas. N Engl J Med. 2004;350:1328–37.

    Article  CAS  PubMed  Google Scholar 

  35. Styczynski J, van der Velden W, Fox CP, et al. Management of Epstein-Barr Virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: sixth European Conference on Infections in Leukemia (ECIL-6) guidelines. Haematologica. 2016;101:803–11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Choquet S, Leblond V, Herbrecht R, et al. Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study. Blood. 2006;107:3053–7.

    Article  CAS  PubMed  Google Scholar 

  37. Zimmermann H, Trappe RU. Therapeutic options in post-transplant lymphoproliferative disorders. Ther Adv Hematol. 2011;2:393–407.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Trappe R, Oertel S, Leblond V, et al. Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial. Lancet Oncol. 2012;13:196–206.

    Article  CAS  PubMed  Google Scholar 

  39. Bollard CM, Gottschalk S, Torrano V, et al. Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins. J Clin Oncol. 2014;32:798–808.

    Article  CAS  PubMed  Google Scholar 

  40. Icheva V, Kayser S, Wolff D, et al. Adoptive transfer of epstein-barr virus (EBV) nuclear antigen 1-specific t cells as treatment for EBV reactivation and lymphoproliferative disorders after allogeneic stem-cell transplantation. J Clin Oncol. 2013;31:39–48.

    Article  CAS  PubMed  Google Scholar 

  41. Leen AM, Bollard CM, Mendizabal AM, et al. Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation. Blood. 2013;121:5113–23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Styczynski J, Reusser P, Einsele H, et al. Management of HSV, VZV and EBV infections in patients with hematological malignancies and after SCT: guidelines from the Second European Conference on Infections in Leukemia. Bone Marrow Transplant. 2009;43:757–70.

    Article  CAS  PubMed  Google Scholar 

  43. Zerr DM, Corey L, Kim HW, et al. Clinical outcomes of human herpesvirus 6 reactivation after hematopoietic stem cell transplantation. Clin Infect Dis. 2005;40:932–40.

    Article  PubMed  Google Scholar 

  44. Seto WK, Sau-Yan Chan T, Hwang YY, et al. Hepatitis B reactivation in occult viral carriers undergoing hematopoietic stem cell transplantation: a prospective study. Hepatology. 2016;65:1451–1461

    Google Scholar 

  45. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol. 2012;57:167–85.

    Article  Google Scholar 

  46. Mallet V, van Bommel F, Doerig C, et al. Management of viral hepatitis in patients with haematological malignancy and in patients undergoing haemopoietic stem cell transplantation: recommendations of the 5th European Conference on Infections in Leukaemia (ECIL-5). Lancet Infect Dis. 2016;16:606–17.

    Article  PubMed  Google Scholar 

  47. Juan J, Feld JJ. Hepatitis B virus and hepatitis C virus treatment and management in patients receiving immune-modifying agents. Curr Opin Rheumatol. 2014;26:395–403.

    Article  CAS  PubMed  Google Scholar 

  48. Oliver NT, Nieto YL, Blechacz B, et al. Severe hepatitis C reactivation as an early complication of hematopoietic cell transplantation. Bone Marrow Transplant. 2017;52:138–40.

    Article  CAS  PubMed  Google Scholar 

  49. European Association for Study of Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol. 2014;60:392–420.

    Article  Google Scholar 

  50. Zeraati AA, Nazemian F, Takalloo L, et al. The relationship between serology of hepatitis E virus with liver and kidney function in kidney transplant patients. EXCLI J. 2016;15:343–9.

    PubMed  PubMed Central  Google Scholar 

  51. Kamar N, Selves J, Mansuy JM, et al. Hepatitis E virus and chronic hepatitis in organ-transplant recipients. N Engl J Med. 2008;358:811–7.

    Article  CAS  PubMed  Google Scholar 

  52. Leung AY, Chan M, Cheng VC, et al. Quantification of adenovirus in the lower respiratory tract of patients without clinical adenovirus-related respiratory disease. Clin Infect Dis. 2005;40:1541–4.

    Article  PubMed  Google Scholar 

  53. Matthes-Martin S, Feuchtinger T, Shaw PJ, et al. European guidelines for diagnosis and treatment of adenovirus infection in leukemia and stem cell transplantation: summary of ECIL-4 (2011). Transpl Infect Dis. 2012;14:555–63.

    Article  CAS  PubMed  Google Scholar 

  54. Grimley MS, Chemaly RF, Englund JA, et al. Brincidofovir for asymptomatic adenovirus viremia in pediatric and adult allogeneic hematopoietic cell transplant recipients: a randomized placebo-controlled phase II trial. Biol Blood Marrow Transplant. 2017;23(3):512–21.

    Article  CAS  PubMed  Google Scholar 

  55. Horlock C, Skulte A, Mitra A, et al. Manufacture of GMP-compliant functional adenovirus-specific T-cell therapy for treatment of post-transplant infectious complications. Cytotherapy. 2016;18:1209–18.

    Article  CAS  PubMed  Google Scholar 

  56. Abudayyeh A, Hamdi A, Abdelrahim M, et al. Poor immune reconstitution is associated with symptomatic BK polyomavirus viruria in allogeneic stem cell transplant recipients. Transpl Infect Dis. 2017. [E-pub 2016]

    Google Scholar 

  57. Ruggeri A, Roth-Guepin G, Battipaglia G, et al. Incidence and risk factors for hemorrhagic cystitis in unmanipulated haploidentical transplant recipients. Transpl Infect Dis. 2015;17:822–30.

    Article  CAS  PubMed  Google Scholar 

  58. Silva Lde P, Patah PA, Saliba RM, et al. Hemorrhagic cystitis after allogeneic hematopoietic stem cell transplants is the complex result of BK virus infection, preparative regimen intensity and donor type. Haematologica. 2010;95:1183–90.

    Article  PubMed  Google Scholar 

  59. Sun YQ, Xu LP, Liu DH, et al. The incidence and risk factors of invasive fungal infection after haploidentical haematopoietic stem cell transplantation without in vitro T-cell depletion. Clin Microbiol Infect. 2012;18:997–1003.

    Article  PubMed  Google Scholar 

  60. Hassler A, Lieb A, Seidel D, et al. Disseminated fusariosis in immunocompromised children-analysis of recent cases identified in the global fungiscope registry. Pediatr Infect Dis J. 2017;36:230–1.

    Article  PubMed  Google Scholar 

  61. Lehrnbecher T, Becker K, Groll AH. Current algorithms in fungal diagnosis in the immunocompromised host. Methods Mol Biol. 2017;1508:67–84.

    Article  PubMed  Google Scholar 

  62. Groll AH, Castagnola E, Cesaro S, et al. Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or allogeneic haemopoietic stem-cell transplantation. Lancet Oncol. 2014;15:e327–40.

    Article  PubMed  Google Scholar 

  63. Tragiannidis A, Roilides E, Walsh TJ, et al. Invasive aspergillosis in children with acquired immunodeficiencies. Clin Infect Dis. 2012;54:258–67.

    Article  PubMed  Google Scholar 

  64. Lehrnbecher T, Schmidt S, Tramsen L, et al. Immunotherapy of invasive fungal infection in hematopoietic stem cell transplant recipients. Front Oncol. 2013;3:17.

    Article  PubMed  PubMed Central  Google Scholar 

  65. Vermeulen E, Lagrou K, Verweij PE. Azole resistance in Aspergillus fumigatus: a growing public health concern. Curr Opin Infect Dis. 2013;26:493–500.

    Article  CAS  PubMed  Google Scholar 

  66. Lescar J, Meyer I, Akshita K, et al. Aspergillus fumigatus harbouring the sole Y121F mutation shows decreased susceptibility to voriconazole but maintained susceptibility to itraconazole and posaconazole. J Antimicrob Chemother. 2014;69(12):3244–7.

    Article  CAS  PubMed  Google Scholar 

  67. Montesinos I, Dodemont M, Lagrou K, et al. New case of azole-resistant Aspergillus fumigatus due to TR46/Y121F/T289A mutation in Belgium. J Antimicrob Chemother. 2014;69(12):3439–40.

    Article  CAS  PubMed  Google Scholar 

  68. Spiess B, Postina P, Reinwald M, et al. Incidence of Cyp51 A key mutations in Aspergillus fumigatus-a study on primary clinical samples of immunocompromised patients in the period of 1995-2013. PLoS One. 2014;9:e103113.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  69. De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008;46:1813–21.

    Article  PubMed  PubMed Central  Google Scholar 

  70. Maertens J, Theunissen K, Verhoef G, et al. Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis. 2005;41:1242–50.

    Article  CAS  PubMed  Google Scholar 

  71. Maertens J, Verhaegen J, Demuynck H, et al. Autopsy-controlled prospective evaluation of serial screening for circulating galactomannan by a sandwich enzyme-linked immunosorbent assay for hematological patients at risk for invasive Aspergillosis. J Clin Microbiol. 1999;37:3223–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  72. Maertens J, Theunissen K, Verbeken E, et al. Prospective clinical evaluation of lower cut-offs for galactomannan detection in adult neutropenic cancer patients and haematological stem cell transplant recipients. Br J Haematol. 2004;126:852–60.

    Article  CAS  PubMed  Google Scholar 

  73. Maertens J, Verhaegen J, Lagrou K, et al. Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation. Blood. 2001;97:1604–10.

    Article  CAS  PubMed  Google Scholar 

  74. Sulahian A, Boutboul F, Ribaud P, et al. Value of antigen detection using an enzyme immunoassay in the diagnosis and prediction of invasive aspergillosis in two adult and pediatric hematology units during a 4-year prospective study. Cancer. 2001;91:311–8.

    Article  CAS  PubMed  Google Scholar 

  75. Ruhnke M, Bohme A, Buchheidt D, et al. Diagnosis of invasive fungal infections in hematology and oncology--guidelines from the Infectious Diseases Working Party in Haematology and Oncology of the German Society for Haematology and Oncology (AGIHO). Ann Oncol. 2012;23:823–33.

    Article  CAS  PubMed  Google Scholar 

  76. Groll AH, Schrey D, Tragiannidis A, et al. Invasive aspergillosis in children and adolescents. Curr Pharm Des. 2013;19:3545–68.

    Article  CAS  PubMed  Google Scholar 

  77. Duarte RF, Sanchez-Ortega I, Cuesta I, et al. Serum galactomannan-based early detection of invasive aspergillosis in hematology patients receiving effective antimold prophylaxis. Clin Infect Dis. 2014;59:1696–702.

    Article  CAS  PubMed  Google Scholar 

  78. Pfeiffer CD, Fine JP, Safdar N. Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis. Clin Infect Dis. 2006;42:1417–27.

    Article  CAS  PubMed  Google Scholar 

  79. Lehrnbecher T, Robinson PD, Fisher BT, et al. Galactomannan, beta-D-glucan, and polymerase chain reaction-based assays for the diagnosis of invasive fungal disease in pediatric cancer and hematopoietic stem cell transplantation: a systematic review and meta-analysis. Clin Infect Dis. 2016;63:1340–8.

    Article  PubMed  Google Scholar 

  80. Lamoth F, Cruciani M, Mengoli C, et al. Beta-Glucan antigenemia assay for the diagnosis of invasive fungal infections in patients with hematological malignancies: a systematic review and meta-analysis of cohort studies from the Third European Conference on Infections in Leukemia (ECIL-3). Clin Infect Dis. 2012;54:633–43.

    Article  PubMed  Google Scholar 

  81. White PL, Barnes RA, Springer J, et al. The clinical performance of Aspergillus PCR when testing serum and plasma- a study by the European Aspergillus PCR Initiative. J Clin Microbiol. 2015;53(9):2832–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  82. Boch T, Spiess B, Cornely OA, et al. Diagnosis of invasive fungal infections in haematological patients by combined use of galactomannan, 1,3-beta-D-glucan, Aspergillus PCR, multifungal DNA-microarray, and Aspergillus azole resistance PCRs in blood and bronchoalveolar lavage samples: results of a prospective multicentre study. Clin Microbiol Infect. 2016;22:862–8.

    Article  CAS  PubMed  Google Scholar 

  83. Caillot D, Couaillier JF, Bernard A, et al. Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia. J Clin Oncol. 2001;19:253–9.

    Article  CAS  PubMed  Google Scholar 

  84. Legouge C, Caillot D, Chretien ML, et al. The reversed halo sign: pathognomonic pattern of pulmonary mucormycosis in leukemic patients with neutropenia? Clin Infect Dis. 2014;58:672–8.

    Article  CAS  PubMed  Google Scholar 

  85. Thomas KE, Owens CM, Veys PA, et al. The radiological spectrum of invasive aspergillosis in children: a 10-year review. Pediatr Radiol. 2003;33:453–60.

    Article  PubMed  Google Scholar 

  86. Burgos A, Zaoutis TE, Dvorak CC, et al. Pediatric invasive aspergillosis: a multicenter retrospective analysis of 139 contemporary cases. Pediatrics. 2008;121:e1286–94.

    Article  PubMed  Google Scholar 

  87. Broenen E, Mavinkurve-Groothuis A, Kamphuis-van Ulzen K, et al. Screening of the central nervous system in children with invasive pulmonary aspergillosis. Med Mycol Case Rep. 2014;4:8–11.

    Article  PubMed  PubMed Central  Google Scholar 

  88. Marzolf G, Sabou M, Lannes B, et al. Magnetic resonance imaging of cerebral aspergillosis: imaging and pathological correlations. PLoS One. 2016;11:e0152475.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  89. Cornely OA, Bangard C, Jaspers NI. Hepatosplenic candidiasis. Clin Liver Dis. 2015;6:47–50.

    Article  Google Scholar 

  90. Oren I, Haddad N, Finkelstein R, et al. Invasive pulmonary aspergillosis in neutropenic patients during hospital construction: before and after chemoprophylaxis and institution of HEPA filters. Am J Hematol. 2001;66:257–62.

    Article  CAS  PubMed  Google Scholar 

  91. Charalampos D, Athanassiadou F. Primary and secondary antifungal prophylaxis in the immunocompromised child: where do we stand? Curr Fungal Infect Rep. 2013;7:1–7.

    Article  Google Scholar 

  92. Science M, Robinson PD, MacDonald T, et al. Guideline for primary antifungal prophylaxis for pediatric patients with cancer or hematopoietic stem cell transplant recipients. Pediatr Blood Cancer. 2014;61:393–400.

    Article  PubMed  Google Scholar 

  93. Maertens J, Marchetti O, Herbrecht R, et al. European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3--2009 update. Bone Marrow Transplant. 2011;46:709–18.

    Article  CAS  PubMed  Google Scholar 

  94. Zhao YJ, Khoo AL, Tan G, et al. Network meta-analysis and pharmacoeconomic evaluation of fluconazole, itraconazole, posaconazole, and voriconazole in invasive fungal infection prophylaxis. Antimicrob Agents Chemother. 2015;60:376–86.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  95. Wingard JR, Carter SL, Walsh TJ, et al. Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. Blood. 2010;116:5111–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  96. Hope WW, Billaud EM, Lestner J, et al. Therapeutic drug monitoring for triazoles. Curr Opin Infect Dis. 2008;21:580–6.

    Article  CAS  PubMed  Google Scholar 

  97. Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med. 2007;356:335–47.

    Article  CAS  PubMed  Google Scholar 

  98. Park S, Kim K, Jang JH, et al. Randomized trial of micafungin versus fluconazole as prophylaxis against invasive fungal infections in hematopoietic stem cell transplant recipients. J Infect. 2016;73:496–505.

    Article  PubMed  Google Scholar 

  99. Andes D. Optimizing antifungal choice and administration. Curr Med Res Opin. 2013;29(Suppl 4):13–8.

    Article  CAS  PubMed  Google Scholar 

  100. Black KE, Baden LR. Fungal infections of the CNS: treatment strategies for the immunocompromised patient. CNS Drugs. 2007;21:293–318.

    Article  CAS  PubMed  Google Scholar 

  101. Coulter KS, Bariola JR. Current antifungal agents for treatment of central nervous system infections. Curr Fungal Infect Rep. 2014;8:146–52.

    Article  Google Scholar 

  102. Cordonnier C, Pautas C, Maury S, et al. Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial. Clin Infect Dis. 2009;48:1042–51.

    Article  CAS  PubMed  Google Scholar 

  103. Tissot F, Agrawal S, Pagano L, et al. ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients. Haematologica. 2017;102:433–444.

    Google Scholar 

  104. Cordonnier C, Maury S, Pautas C, et al. Secondary antifungal prophylaxis with voriconazole to adhere to scheduled treatment in leukemic patients and stem cell transplant recipients. Bone Marrow Transplant. 2004;33:943–8.

    Article  CAS  PubMed  Google Scholar 

  105. Cordonnier C, Rovira M, Maertens J, et al. Voriconazole for secondary prophylaxis of invasive fungal infections in allogeneic stem cell transplant recipients: results of the VOSIFI study. Haematologica. 2010;95:1762–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  106. Beck O, Koehl U, Tramsen L, et al. Enumeration of functionally active anti-Aspergillus T-cells in human peripheral blood. J Immunol Methods. 2008;335:41–5.

    Article  CAS  PubMed  Google Scholar 

  107. Lehrnbecher T, Kalkum M, Champer J, et al. Immunotherapy in invasive fungal infection--focus on invasive aspergillosis. Curr Pharm Des. 2013;19:3689–712.

    Article  CAS  PubMed  Google Scholar 

  108. Caselli D, Petris MG, Rondelli R, et al. Single-day trimethoprim/sulfamethoxazole prophylaxis for Pneumocystis pneumonia in children with cancer. J Pediatr. 2014;164:389–92 e1.

    Article  CAS  PubMed  Google Scholar 

  109. Maertens J, Cesaro S, Maschmeyer G, et al. ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients. J Antimicrob Chemother. 2016;71:2397–404.

    Article  CAS  PubMed  Google Scholar 

  110. Atilla Ataca, P, Atilla, E, Bozdağ, SC, Demirer, T. A review of infectious complications after haploidentical hematopoietic stem cell transplantations. Infection, 2017. In print. doi:10.1007/s15010-017-1016-1.

Download references

Author information

Authors and Affiliations

  1. University Hospital Frankfurt, Department for Children and Adolescents, Goethe University Frankfurt, Theodor Stern Kai 7, 60590, Frankfurt, Germany

    Angela Haßler, Thomas Lehrnbecher, Peter Bader & Thomas Klingebiel

Authors
  1. Angela Haßler
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Thomas Lehrnbecher
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Peter Bader
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Thomas Klingebiel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Thomas Klingebiel .

Editor information

Editors and Affiliations

  1. Department of Hematology, Ankara University Medical School, Sıhhiye, Ankara, Turkey

    Taner Demirer

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing AG

About this chapter

Cite this chapter

Haßler, A., Lehrnbecher, T., Bader, P., Klingebiel, T. (2017). Prevention and Treatment of Infectious Complications in Haploidentical SCT. In: Demirer, T. (eds) Haploidentical Stem Cell Transplantation. Stem Cell Biology and Regenerative Medicine. Humana Press, Cham. https://doi.org/10.1007/978-3-319-65319-8_6

Download citation

Publish with us

Policies and ethics

Search

Navigation